ADVANCED THERAPEUTICS
www.advtherap.com

REVIEW

Synergistic Integration of Artificial Intelligence, Organoid Models, and Multi-Omics Technologies in Contemporary Drug Discovery

Yuvaraj Dinakarkumar[1] | Saravana Kumar Ganesan[2] | Rinish Mortin John[3] | Aishwarya Lakshmi Thasvanth Raj[3] | Harshaveena Raja[3] | Arokiyaraj Selvaraj[4] | N. Punitha[5] | Venkatesh Alagarsamy[6]

[1]Department of Biotechnology, School of Life Sciences, Vels Institute of Science, Technology and Advanced Studies (VISTAS), Chennai, Tamil Nadu, India | [2]Department of Computer Science Engineering, Karpagam Academy of Higher Education (Deemed University), Coimbatore, Tamil Nadu, India | [3]Department of Biotechnology, Vel Tech High Tech Dr. Rangarajan Dr. Sakunthala Engineering College, Avadi, Chennai, India | [4]Department of Food Science & Biotechnology and Carbohydrate Bioproduct Research Center, Sejong University, South Korea | [5]Department of Physics, St. Joseph's College of Engineering, Chennai, Tamil Nadu, India | [6]Dept. Of Conservative Dentistry & Endodontics, Sree Balaji Dental College & Hospital, Bharat Institute of Higher Education & Research (BIHER), Chennai, Tamil Nadu, India

Correspondence: Yuvaraj Dinakarkumar (yuvarajd.sls@vistas.ac.in)

Received: 28 October 2025 | **Revised:** 8 December 2025 | **Accepted:** 11 December 2025

Keywords: artificial intelligence | drug discovery | high-throughput screening | multi-omics | organoids | translational research

ABSTRACT

The integration of advanced biotechnology platforms is revolutionizing the drug discovery landscape, enhancing efficiency and success rates while reducing development costs. This review examines the convergence of artificial intelligence (AI), high-throughput screening, organoid technology, and multi-omics approaches in drug development. AI and machine learning algorithms leverage big data to predict drug-target interactions, optimize molecular structures, and identify novel therapeutic candidates. Organoid-based in vitro models, complex 3D cellular constructs derived from stem cells, recapitulate human disease biology than conventional 2D cell cultures, improving the predictive power of preclinical efficacy and toxicity testing. High-throughput phenotypic screening, enhanced by automation, enables testing of vast compound libraries in physiologically relevant cell systems. Multi-omics technologies (genomics, proteomics, and metabolomics) yield comprehensive molecular profiles of disease states and drug responses. AI-driven predictions can be experimentally validated in organoid models, while organoid-derived data feed back into machine learning models to refine predictions. Current challenges, including standardization of organoid culture protocols, validation of AI model predictions, and the management of multi-modal big data are critically examined. Emerging trends and future directions are presented, highlighting the potential of these integrated approaches to accelerate the development of personalized therapies and reduce attrition rates in clinical trials.

1 | Introduction

Drug discovery has undergone a profound transformation over the past few decades, evolving from serendipitous findings into a highly systematic, technology-driven enterprise [1, 2]. The traditional linear pipeline from target identification and lead discovery through preclinical testing and clinical trials has proven both costly and inefficient, with average development times of 10–15 years and costs exceeding $2.6 billion per new drug [3]. Attrition rates remain dauntingly high: approximately 90% of drug candidates that enter clinical trials ultimately fail to achieve regulatory approval, often due to lack of efficacy or unforeseen

safety issues [4]. These challenges are frequently attributed to limitations of conventional discovery tools; for instance, target-centric approaches can falter if the chosen target is not critical in human disease, and simplistic 2D cell cultures or animal models often fail to predict human clinical outcomes [5, 6]. The complexity of human diseases, particularly in oncology, neurology, and rare genetic disorders demands more advanced and predictive models that can account for genetic heterogeneity, network-level pathophysiology, and patient-specific responses [5, 7].

In response to these issues, the pharmaceutical research community is increasingly embracing innovative biotechnological platforms to enhance every stage of the drug discovery and development process [3]. Advanced computational methods, novel in vitro models, and comprehensive multi-omics profiling techniques have each shown the capacity to improve target identification, lead optimization, and preclinical validation [7, 8]. Importantly, the convergence of these diverse technologies offers synergistic capabilities beyond what any single approach can achieve on its own. By integrating powerful computational algorithms with physiologically relevant experimental models and rich molecular datasets, researchers aim to create a more predictive and efficient drug discovery paradigm [9]. This review focuses on four key platform categories that exemplify this integration: (1) artificial intelligence and machine learning for drug discovery, (2) high-throughput and phenotypic screening technologies, (3) genomic and multi-omics tools, and (4) organoid-based and other advanced 3D cell culture systems. We discuss each of these areas and then explore how they can be strategically combined to address current challenges in translational medicine [10]. We also consider the practical hurdles from data management to regulatory acceptance that must be overcome to fully realize the benefits of an integrated biotechnology-driven drug discovery ecosystem [11]. Finally, we outline future directions and emerging trends that are likely to shape the next generation of pharmaceutical research [12].

2 | Technological Platforms Transforming Drug Discovery

2.1 | Artificial Intelligence and Machine Learning

Artificial intelligence (AI) and machine learning (ML) have emerged as transformative technologies in drug discovery, enabling researchers to analyze vast datasets, identify patterns, and make predictions that would be impossible with traditional methods [13, 14] (Figure 1). AI encompasses a broad range of computational approaches that simulate human intelligence, while ML refers to algorithms that learn from and make predictions based on data without being explicitly programmed [15, 16]. Deep learning, a subset of ML based on artificial neural networks with multiple layers, has shown particular promise in drug discovery applications [17]. These algorithms can process complex, high-dimensional data and extract meaningful features that aid in target identification, molecular design, and activity prediction. Convolutional neural networks (CNNs), originally developed for image recognition, have been adapted for molecular structure analysis and binding site prediction [18]. Recurrent neural networks (RNNs) have been applied to sequence-based predictions



FIGURE 1 | AI enabled workflows across drug discovery, including target identification, virtual screening, molecular optimization, toxicity prediction and patient stratification. The figure highlights the versatility of machine learning and deep learning approaches. Diagram includes common AI methods (CNNs, RNNs, GNNs), integrates them with cheminformatics pipelines and shows how these models predict activity, prioritize chemical libraries and support clinical trial design. Icons denote each application area.

and generation of novel molecular structures [3, 19]. ML models trained on known active and inactive compounds can screen virtual libraries containing millions of compounds to identify potential hits, significantly reducing the number of compounds that need to be physically tested [20]. Generative models can design novel molecular structures with desired properties, exploring chemical space more efficiently than traditional approaches [21]. AI algorithms can analyze biological networks and multi-omics data to identify novel targets and predict disease-relevant pathways [22]. ML models trained on toxicity databases can predict potential safety issues early in development, reducing late-stage failures [23]. AI can improve patient selection, identify relevant biomarkers, and predict treatment responses, potentially increasing success rates in clinical trials [15]. Notable success stories include the use of AI by in silico Medicine to identify novel DDR1 kinase inhibitors in just 46 days, compared to the years typically required by traditional approaches [17]. Similarly, Exscientia's AI platform enabled the discovery of DSP-1181, a serotonin 5-HT1A receptor agonist for obsessive-compulsive disorder, which entered clinical trials in 2020 after just 12 months of development [24]. Continuing these advances, in silico Medicine reported in 2022 that it advanced an AI-identified target (the kinase TNIK) and an AI-designed small molecule for idiopathic pulmonary fibrosis from program initiation to Phase I human trials in under 30 months [24, 25]. This rapid progression, unprecedented for an internally developed program, highlights AI's accelerating impact on target discovery and lead optimization. More recently, this AI-designed compound (now called rentosertib) has moved into Phase II trials for fibrosis, marking a milestone where both the target and therapeutic were discovered using generative AI [26]. These examples underscore



FIGURE 2 | A cross platform drug discovery pipeline showing how AI, compound libraries, primary screens, secondary validation and in vivo modelling interact in an iterative process. Arrows represent progression from virtual screening to cell based assays and in vivo studies. Boxes illustrate each stage, including phenotypic screening, molecular docking and mechanism of action validation. Coolers distinguish computational vs biological workflows.

how AI-driven approaches are shortening development timelines and expanding the scope of druggable space beyond conventional targets.

2.1.1 | High-Throughput and Phenotypic Screening

High-throughput screening (HTS) has long been a cornerstone of lead discovery, allowing researchers to test hundreds of thousands to millions of compounds for biological activity in a relatively short time frame [27] (Figure 2). Recent technological advances have further enhanced the throughput and informational content of screening campaigns. Automated robotic platforms and miniaturized assay formats (1536-well plates and beyond) have significantly increased screening efficiency while reducing reagent costs [28]. Moreover, high-content screening (HCS) approaches now combine the scale of HTS with rich phenotypic readouts by incorporating automated microscopy and image analysis. In HCS, cells are exposed to libraries of compounds and then imaged for changes in morphology, marker expression, or organelle status; machine vision algorithms can quantify dozens of features per cell, turning each experiment into a multiparametric phenotypic profile [29]. Such phenotypic screening is especially powerful for diseases with complex or unknown mechanisms, as it does not require a predefined molecular target. Indeed, analyses have shown that phenotypic screens have led to a higher proportion of first-in-class medicines than target-based approaches, likely because they allow discovery of drugs acting on novel or multiple pathways [14].

Modern phenotypic screening can also incorporate functional genomics tools to aid target deconvolution: for instance, coupling a small-molecule screen with a CRISPR-Cas9 knockout library can identify which genes modulate a compound's activity, thereby revealing the compound's likely targets or resistance mechanisms [30]. Alongside improvements in assay throughput and complexity, novel screening paradigms have emerged. Label-free detection technologies such as surface plasmon resonance and impedance-based sensors enable the real-time monitoring of biomolecular interactions or cell physiology without the need for fluorescent or radioactive labels [31]. These methods can capture subtler effects on target binding kinetics or cell morphology, providing additional dimensions of data for each test compound. In parallel, microfluidic and droplet-based screening platforms have miniaturized experiments to the scale of micro- or picolitters, dramatically increasing screening density and allowing precise control of cellular microenvironments [32]. For example, droplet microfluidics can compartmentalize single cells or small



FIGURE 3 | A schematic showing the convergence of genomics, transcriptomics, proteomics, metabolomics and epigenomics to generate an integrated molecular landscape for target identification and mechanistic characterization. Each omics layer is represented as a data module feeding into an integrative computational framework. Networks symbolize correlations, pathway mapping and feature extraction steps necessary for multi-level interpretation.

clusters with different compounds in tiny emulsified droplets, enabling massively parallel phenotypic assays. Similarly, organ-on-chip devices use microfluidic channels to culture cells under flow conditions, recapitulating aspects of tissue biomechanics and cell-cell interactions that static cultures lack [33]. By integrating human-derived cells (including stem-cell-derived tissues or organoids) into HTS and microfluidic platforms, researchers can perform screening campaigns that are not only high-throughput but also high-fidelity in modelling human biology. The result is a screening toolkit that can efficiently find hits with greater likelihood of translating into in vivo efficacy. Still, the deluge of data produced by modern screening methods demands advanced data analytics (often AI-assisted) to interpret, and screening complex cellular models (like organoids) poses practical challenges in consistency and analysis, which we discuss in later sections [34].

2.2 | Genomic and Multi-Omics Technologies

The advent of next-generation sequencing (NGS) and other high-throughput "omics" techniques has equipped drug discovery with an unprecedented ability to characterize the molecular underpinnings of diseases and drug actions [35]. Genomics particularly through whole-genome or exome sequencing can reveal genetic mutations and variants associated with disease, yielding new drug targets (Figure 3). Large-scale genomics efforts, such as cancer genome atlases, have provided catalogues of actionable mutations that guide targeted therapy development [14]. Beyond DNA, transcriptomic profiling (RNA sequencing) identifies genes and pathways dysregulated in disease states or in response to treatments, aiding in target identification and biomarker discovery [4]. Crucially, functional genomics tools like CRISPR-Cas9 and RNA interference (RNAi) have enabled systematic perturbation of genes to validate their roles as potential drug targets [29]. CRISPR screening can knock out or modify thousands of genes in parallel in cell models to pinpoint which gene's loss mimics a disease phenotype or confers drug resistance, thus highlighting high-value targets or drug resistance mechanisms. Such genome-scale loss-of-function or gain-of-function screens have become invaluable in identifying and prioritizing drug targets, especially when combined with complementary data for example, integrating CRISPR screen results with Tumor genomic data to find Tumor "addictions" [36].

Proteomics adds another critical layer of insight by measuring protein expression levels, post-translational modifications, and protein-protein interactions directly [37]. Since proteins are the effectors of most drug actions, proteomic changes often correlate more directly with phenotypic outcomes than transcript changes. Advances in mass spectrometry (MS)-based proteomics now allow near-quantitative comparison of thousands of proteins across different conditions or samples [38]. This has led to the discovery of disease-specific protein biomarkers and pathways that genomics alone might miss. Proteomic techniques like thermal proteome profiling and chemical proteomics can also identify the molecular targets of drug candidates by detecting proteins that physically interact with compounds or whose thermal stability is altered upon drug binding [37]. Additionally, mapping protein-protein interaction networks through affinity-purification MS or proximity labelling can uncover key nodes in signalling networks that could be therapeutic intervention points. Metabolomics, though not as widely applied in early discovery, provides information on the biochemical pathways and metabolite levels in cells or organisms, which is particularly

useful for understanding drug mechanisms and off-target effects on metabolism [39].

Individually, each omics modality provides a snapshot of biological activity; however, it is their integration multi-omics analysis that yields a more holistic understanding of disease and drug response [39]. Multi-omics studies might combine genomic, epigenomic, transcriptomic, proteomic, and metabolomic data from the same system to build a comprehensive model of how a drug perturbs the biological network. For example, integrating proteomic data with parallel CRISPR essentiality screens and transcriptomics can prioritize drug targets that are not only genetically essential to a cancer cell but also highly expressed or uniquely modified in Tumors [36]. Single-cell omics has further added to this richness by resolving heterogeneity: single-cell RNA sequencing and mass cytometry (single-cell proteomics) reveal that seemingly uniform cell populations actually consist of distinct subpopulations, which can have differential drug sensitivities [40]. Identifying these subpopulations helps in understanding why a drug might work in some patients or cell subclones but not others, informing combination strategies to prevent resistance and guiding patient stratification in clinical trials [32].

The challenge accompanying multi-omics is the sheer complexity and volume of data generated. Advanced bioinformatics and machine learning methods are essential to integrate these layers into coherent insights. When done successfully, multi-omics integration can pinpoint critical "nodes" in disease networks as the most promising drug targets, suggest mechanism-based combination therapies, and uncover biomarkers that predict which patients will benefit from a given therapy [41]. In this review, we highlight how multi-omics approaches have been used in drug discovery to identify novel targets (e.g., by combining cancer genome sequencing with CRISPR screens) and to characterize drug mechanisms (e.g., using proteomics to find the targets of phenotypic screening hits). The synergy between multi-omics data and AI-based analysis is a recurring theme, as computational tools are increasingly indispensable for extracting actionable knowledge from complex datasets [42].

2.3 | Organoids and Advanced 3D Cell Cultures

Organoid technology represents a breakthrough in creating more physiologically relevant in vitro models of human tissues [34]. Organoids are 3D, self-organizing cellular structures, typically derived from pluripotent stem cells or adult stem/progenitor cells that can recapitulate key architectural and functional features of real organs [43]. Over the past decade, protocols have been developed to grow organoids corresponding to many organs' intestine, liver, pancreas, kidney, brain, lung, among others, each exhibiting cell-type diversity and organization resembling their in vivo counterparts (Figure 4). In drug discovery, organoids offer *disease models* that often capture patient-specific characteristics, especially when organoids are derived from patient Tumor samples or diseased tissues [44]. Tumor organoids established from individual patients have been shown to mirror the histopathological and genomic features of the original Tumor, as well as the patient's responses to chemotherapy in the clinic [34]. Similarly, cystic fibrosis patient-derived intestinal organoids have been used to test CFTR modulator drugs ex vivo, accurately predicting which patients have sufficient functional improvement to benefit from certain therapies [45]. These cases underscore the potential of organoids in personalized medicine using ex vivo patient-derived models to guide therapy selection and development.

Beyond personalized models, organoids provide generally improved predictors of drug efficacy and toxicity due to their more realistic microanatomy and cell-cell interactions. In contrast to conventional 2D cell monolayers, organoids develop nutrient gradients, hypoxic cores, and differentiated cell lineages that influence drug penetration and metabolism, thus better mimicking in vivo drug responses [46]. Organoids have been successfully implemented in drug screening pipelines, with adaptations to grow organoids in multi-well formats and perform automated readouts for viability or other phenotypes [34, 43]. Pharmaceutical companies have started to invest in organoid platforms: for instance, Roche has used large collections of Tumor organoids to identify predictive biomarkers of drug response, and Janssen has explored kidney organoids for nephrotoxicity testing of candidates. These initiatives reflect a broader industry trend toward micro physiological systems, wherein human-derived 3D models (organoids, tissue chips) are incorporated alongside traditional animal studies to improve decision-making in preclinical development [47] (Figure 5).

Despite their promise, organoids come with certain practical challenges. They can exhibit variability in size, cellular composition, and maturation state, even when derived from the same source, which complicates reproducibility and assay readouts [48]. Additionally, most organoids lack vasculature and immune system components unless specifically co-cultured with those elements, meaning they do not fully recapitulate drug delivery or immunological aspects of disease. Recent literature highlights ongoing advances in organoid maturation, microenvironment engineering and functional readouts that enhance their predictive value for therapeutic screening [49–51]. Efforts are underway to overcome these limitations: co-culture systems that add immune cells or stromal support to organoids are being developed [52], and bioengineering approaches like 3D bioprinting and scaffold-based growth aim to impose more control over organoid structure and vascularization. 3D bioprinting can position cells and biomaterials in predefined architectures to create organotypic constructs with perfusable channels, improving nutrient supply and waste removal in large organoids [47]. Meanwhile, simpler 3D culture models such as spheroids (multicellular aggregates) are also widely used, as they are easier to produce and more amenable to high-throughput formats, albeit with less complexity than organoids. Spheroids composed of cancer cell lines or mixed cell types can serve as intermediate models for compound screening before advancing to more complex organoids or in vivo models [53]. Advanced 3D cell culture systems like organoids are closing the gap between traditional in vitro assays and human biology. They provide more predictive platforms for evaluating drug candidates, especially when it comes to capturing the nuances of human-specific disease processes and drug responses [34]. By integrating organoids into drug discovery workflows like using organoid disease models to validate AI-predicted drug hits or to test combinations identified through multi-omics analysis, researchers can de-risk projects earlier and focus resources on candidates with a higher likelihood of clinical



FIGURE 4 | Representative applications of patient derived tumor organoids, including drug screening, biomarker discovery, genetic engineering and personalized treatment modelling. Organoid images represent different tissue origins. Icons show phenotypic screening, CRISPR editing, biomarker profiling and immune co culture systems. Arrows show how ex vivo responses inform clinical decision making.

success. The subsequent section will delve into such integration strategies, illustrating how these technological platforms can complement one another in a unified drug discovery strategy [47, 48, 52].

To address the well-recognized issue of variability in organoid cultures, several standardization strategies have emerged to enhance reproducibility and cross laboratory comparability. Automated stirred tank bioreactors and microfluidic perfusion systems are increasingly used to regulate nutrient delivery, oxygenation and shear forces, thereby reducing heterogeneity in organoid size and maturation [54]. The development of defined and fully synthetic extracellular matrices offers a more consistent alternative to Matrigel, minimizing batch-to-batch biochemical variation [55]. Reference organoid lines and shared biobank standards, such as those advanced by the Hubrecht Institute and the NIH supported organoid programmes, provide benchmark models for calibration and cross validation between laboratories [56]. Quality control frameworks incorporating automated imaging, machine learning based morphology assessment, transcriptomic fingerprinting and viability metrics are also being implemented to ensure reproducibility before organoids are used in screening or mechanistic studies [57]. These advances collectively demonstrate that organoid platforms are moving toward increasingly standardized, scalable and quality assured systems suitable for translational drug discovery.

2.4 | Integration Strategies for Advanced Technologies

Harnessing the full potential of the aforementioned technologies requires deliberate strategies to integrate computational and experimental platforms into cohesive workflows [15, 18]. One of the central tenets of integration is that the combined use of diverse approaches can yield insights greater than the sum of its parts. A clear example is the iterative loop between AI predictions and organoid validation: AI-driven models can rapidly screen vast chemical space and suggest candidate molecules or targets, but these predictions carry uncertainty until validated in a biological system [58]. By testing top-ranked AI-predicted compounds in organoid or high-fidelity cell models, researchers obtain experimental feedback on activity and toxicity. Those results can then be fed back into machine learning models to refine algorithms (for instance, improving the training dataset with new active and inactive compounds), creating a closed-loop learning system that becomes increasingly predictive over time [29]. Several recent studies demonstrate the practical effectiveness of integrating AI driven predictions with organoid based validation workflows. AI generated network models developed by Roche and the Broad Institute were used to prioritize compound sensitivity patterns in colorectal cancer, and subsequent testing across large panels of patient derived tumor organoids confirmed the predicted drug response signatures and enabled



FIGURE 5 | A circular schematic summarizing organoid applications in disease modelling, drug discovery, toxicology, regenerative medicine and bioengineering. The circular flow denotes the regenerative cycle of organoid use in basic research and applied biotechnology. Images and icons represent organoid biobanks, tissue engineering platforms and multi organ chip integration.

biomarker identification [59]. Deep learning supported structural modelling has also been applied in pancreatic and breast cancer research, where AI predicted ligand–target interactions translated into measurable therapeutic effects in corresponding tumor organoids, validating the computational hypotheses [60]. In hepatocellular carcinoma, multi omics-based machine learning identified essential metabolic targets, which were subsequently verified using CRISPR edited liver organoids that reproduced the expected viability and pathway changes [61]. Pharmaceutical groups such as Janssen and AstraZeneca have reported closed loop discovery systems in which machine learning algorithms predicted nephrotoxic liabilities, and kidney organoids accurately recapitulated the toxicity patterns, outperforming conventional 2D culture assays [62].

Another integration strategy involves merging multi-omics datasets with phenotypic screening outputs to facilitate target identification for phenotypic hits a process known as target deconvolution [22]. Historically, when a compound was discovered through a phenotypic assay, determining its molecular target could take years. Now, integrated approaches can drastically speed this up: one can treat cells or organoids with the compound and perform transcriptomic and proteomic profiling to see which pathways are perturbed [63], use proteomic methods like thermal proteome profiling to directly pull-out protein targets, or employ CRISPR screens to find genes that alter the compound's effect. By overlaying these independent lines of evidence, researchers can quickly converge on the likely target or mechanism of action of a novel bioactive compound. This integration of screening with omics and AI analytics exemplifies how complex datasets can be united to solve a key bottleneck in drug discovery [64].

Data management and infrastructure are foundational to successful integration. The volume and heterogeneity of data produced by AI models, high-throughput assays, genomics, and organoid experiments demand robust bioinformatics pipelines and databases [34]. Cloud-based platforms have become increasingly popular for storing and analysing large datasets collaboratively. They enable teams across disciplines computational scientists, biologists, pharmacologists to access shared data, apply standardized analysis workflows, and collectively interpret findings. Efforts to develop common data standards and ontologies for drug discovery data (e.g., standard formats for single-cell RNA-seq or for chemical structures and bioactivities) help ensure that different datasets can "talk" to each other in integration efforts [65]. In addition, the use of electronic lab notebooks and data lakes that aggregate experimental results allows AI algorithms to mine historical data from many projects to detect patterns that might guide new experiment.

Organizational strategies also play a role in technological integration. Companies and research institutions are increasingly assembling multidisciplinary teams that bring together experts in AI, wet-lab biology, engineering, and clinical research. Such

teams can iterate quickly, as they can design experiments with the end analysis in mind and vice versa [3]. For example, an AI specialist might inform a biologist that a certain type of data (say, high-resolution imaging of cell organelles) would improve a model's predictive power, leading the biologist to incorporate that readout in the organoid assay [63]. In turn, unexpected experimental observations can be rapidly communicated to modelers to adjust their strategy. Some organizations have even co-located wet labs with computation hubs, blurring the line between "in silico" and "in vitro" workflows into a continuous discovery engine [66].

An emerging concept in integration is the "digital twin" of a laboratory experiment or patient, a comprehensive computational model that can be used to simulate and optimize experiments before they are performed physically. In drug discovery, one might envision a digital twin of a disease model that is continuously updated with data from organoids, omics, and clinical trials, allowing in silico testing of new drug ideas or combinations in parallel with real-world experiments [66]. While still in early stages, such visions highlight the direction of travel: deeper integration of data and methods to make drug R&D more predictive, efficient, and adaptable.

Successful integration strategies often involve iterative experimentation guided by AI (closed-loop learning), multi-modal data fusion to reveal actionable insights (e.g., linking phenotypic outcomes to molecular targets), and investments in the infrastructure and culture that facilitate collaboration across traditional disciplinary boundaries [3]. The following sections will address the current challenges that can impede these integration efforts and discuss how the field can navigate issues ranging from technical bottlenecks to regulatory hurdles.

2.4.1 | Challenges and Regulatory Considerations

While the marriage of AI, organoids, multi-omics, and other technologies holds great promise, it also presents a suite of challenges that must be addressed to realize its full benefits in drug discovery [43, 67]. Data quality and standardization is also a fundamental concern. Integrating data from different platforms (e.g., genomic sequencers, imaging systems, and high-throughput screens) can be problematic if those data are noisy or lack standardized formats. Variability in organoid cultures, as mentioned earlier, can lead to inconsistent results, complicating machine learning model training and validation [68]. Similarly, batch effects in omics experiments or biases in training datasets for AI can skew results. The field is actively working on solutions such as improved experimental protocols (to increase reproducibility), reference controls across batches, and algorithmic techniques to correct for batch effects [69]. Quality control (QC) systems are being implemented at both the experimental and computational levels: for example, automated image analysis pipelines may flag organoids that do not meet certain size or morphology criteria for inclusion in analysis, and bioinformatics pipelines can filter out low-confidence omics data. Establishing community-wide standards (for instance, Minimal Information guidelines for reporting organoid experiments or model development) will further help different groups to reproduce and build upon each other's integrative studies [43].

Another challenge is the validation of AI predictions and models. With increasing use of black-box models like deep neural networks, there is a risk of overfitting or of basing decisions on correlations that lack true causal biology. Regulatory agencies and pharmaceutical decision-makers generally require clear evidence for why a drug candidate is expected to work [3]. This means that AI-generated hypotheses often need to be backed by mechanistic understanding. Methods for improving AI interpretability, such as identifying which molecular features or biological pathways were most influential in a prediction are therefore important [16]. In practice, a combination of approaches (integrating empirical rules or known constraints into AI, and using explainable AI techniques) may be needed to ensure that advanced models aid human decision-making rather than confound it. The integration with experimental systems like organoids serves as a real-world filter to verify AI outputs, but this too needs scaling, we must choose which AI predictions to test in costly lab experiments [57]. This triaging itself can be guided by meta-models or by incorporating uncertainty estimates in AI predictions.

Recent regulatory developments provide clearer pathways for integrating AI and advanced in vitro systems such as organoids into mainstream drug development. The FDA Modernization Act 2.0 (2022–2023) represents a major shift by formally allowing non animal test methods, including organoids, tissue chips and computational models, to be used as acceptable evidence in preclinical evaluation [70]. Parallel efforts by the European Medicines Agency (EMA), including recent guidance on the use of AI and machine learning in medicinal product development (2023), outline expectations around data quality, transparency, version control and model explainability [71]. These frameworks signal growing regulatory readiness to evaluate drug candidates supported by AI predictions, multi omics profiling and organoid derived data. For developers, the practical implications include earlier engagement with regulators, stronger documentation of model provenance, adherence to quality by design principles, and the need to demonstrate how outputs from AI or organoid systems directly support safety or efficacy decisions [72]. Incorporating these emerging regulatory standards can streamline approval processes and increase confidence in next generation discovery pipelines.

Regulatory agencies are beginning to incorporate data from both AI driven approaches and organoid based systems into early-stage decision making. The US FDA's Innovative Science and Technology Approaches for New Drugs (ISTAND) programme has accepted organ on chip and organoid platforms for qualification as alternative test methods, including a liver chip model shown to correctly identify hepatotoxic compounds that had passed traditional animal studies [73]. Kidney organoid data have been submitted in preclinical packages by industry groups such as AstraZeneca to support early nephrotoxicity assessment [62]. On the computational side, the FDA and EMA have begun reviewing AI assisted dosing algorithms and model informed drug development tools, with several submissions using machine learning for pharmacokinetic predictions and patient stratification in oncology trials [74]. While these tools do not yet replace standard requirements, they are being used as supportive evidence in regulatory filings, signalling a gradual shift toward acceptance.

Looking ahead, a modernized regulatory framework will need to accommodate the rapid growth of AI, multi omics and advanced

in vitro models. This could include context specific validation pathways that match the level of regulatory scrutiny to the intended use of the technology, clear standards for data provenance and model interpretability, shared benchmarking datasets for AI tools, and cross agency harmonization of expectations for organoid and tissue chip models [75]. Early dialogue between developers and regulators, combined with pilot qualification programmes and adaptive guidance documents, can help ensure that regulatory science evolves alongside technological innovation. Such a framework would support safe and transparent adoption of emerging tools while enabling a more predictive and efficient drug development ecosystem. Although data standardization and multi omics integration remain significant bottlenecks in modern drug discovery, several strategies have already shown success in overcoming these limitations. For multi omics integration, computational frameworks such as network based data fusion, Bayesian multi-layer models and structured sparsity regularization have demonstrated strong performance in harmonizing heterogeneous datasets and identifying convergent biological signals across genomics, transcriptomics, proteomics and metabolomics [76]. Integrated analyses combining CRISPR based functional genomics with proteomic signatures and transcriptomic perturbation profiles have successfully accelerated target identification in cancer models, enabling rapid prioritization of druggable nodes within complex regulatory networks [77]. Deep learning approaches applied to single cell and bulk omics datasets have improved batch correction, reduced noise and enhanced predictive accuracy in pathway level analyses [78]. On the experimental side, efforts to standardize organoid culture systems using defined biomaterials, controlled seeding density, automated imaging and quality control metrics have improved reproducibility across laboratories, allowing organoid derived phenotypic and molecular data to be more reliably incorporated into AI driven and multi omics pipelines [79]. Initiatives such as the Hubrecht Institute's organoid biobank have introduced standard operating procedures for organoid culture, including defined matrices, consistent seeding density and automated imaging, substantially reducing batch variation [80]. These examples demonstrate that well established computational frameworks, harmonized experimental pipelines and multi modal reference datasets can effectively mitigate issues of variability and data fragmentation, strengthening the reliability and interpretability of integrated drug discovery workflows.

2.4.2 | Limitations of AI in Drug Discovery

Despite the rapid progress and expanding capabilities of AI driven drug discovery, several important limitations must be acknowledged to contextualize its practical and scientific boundaries. One of the most significant challenges is data bias, which arises when training datasets are unbalanced, incomplete or not representative of the chemical or biological space relevant to the disease. Models trained on biased datasets may systematically overpredict activity for certain chemotypes, miss rare but important biological interactions, or fail to generalize to new targets or patient populations [81].

Model interpretability also remains a critical barrier. Many deep learning architectures function as black boxes, offering limited insight into the molecular features or biological pathways driving their predictions. This lack of transparency can reduce trust, hinder mechanistic understanding and complicate regulatory evaluation [82]. Overfitting is another key challenge, especially in high dimensional datasets such as transcriptomics, proteomics or large chemical libraries. Without rigorous validation, models may perform well on training data but fail when exposed to new compounds or biological contexts [83].

There is also a growing concern that AI generative models can produce molecules that score highly in silico but are chemically unstable, biologically irrelevant or synthetically infeasible. Ensuring that generated compounds adhere to medicinal chemistry principles and real-world pharmacological constraints remains a major bottleneck [84]. Integrating AI output with wet lab workflows can be limited by prediction uncertainty, lack of assay standardization and the difficulty of translating computational hits into experimentally tractable molecules [85].

Recognizing these pitfalls is essential for developing robust AI enabled pipelines. Addressing them will require higher quality datasets, improved model interpretability tools, integrated medicinal chemistry constraints, stronger benchmarking frameworks and close coupling of computation with biological validation systems such as organoids and high throughput screening platforms.

2.5 | Regulatory Considerations and Challenges

The integration of advanced biotechnology platforms in drug discovery presents significant regulatory considerations and challenges that must be addressed to ensure the safe, effective, and timely development of novel therapeutics [1, 86]. Regulatory frameworks, developed primarily for traditional drug development paradigms, must evolve to accommodate emerging technologies, novel therapeutic modalities, and innovative development approaches while maintaining rigorous standards for patient safety and product efficacy [87]. The dynamic tension between innovation and regulation requires thoughtful engagement from multiple stakeholders, including regulatory agencies, industry, academia, and patient representatives, to develop appropriate oversight mechanisms that protect public health without unnecessarily impeding therapeutic advancement [86].

Key regulatory considerations and challenges related to advanced biotechnology platforms include:

2.5.1 | Qualification and Validation of Novel Methods

Establishing appropriate standards and processes for evaluating the reliability, reproducibility, and relevance of innovative drug discovery technologies, including AI/ML models, organoid systems, and advanced screening platforms [72]. Regulatory agencies face challenges in developing qualification frameworks that are rigorous enough to ensure scientific validity while remaining flexible enough to accommodate rapidly evolving technologies and context-specific applications. Industry and academic researchers, meanwhile, must navigate uncertainty about validation requirements and evidence standards when implementing new approaches in regulatory-facing programs [12]. Notably,

recent policy initiatives signal a shift toward acceptance of novel methodologies. For example, the U.S. FDA Modernization Act 2.0 (enacted in late 2022) removed the mandate for animal testing in new drug applications, allowing sponsors to use advanced non-animal models (such as human cell-based assays, organ-on-chip systems, and computational models) to satisfy preclinical safety requirements [88]. In April 2023, the FDA went further by announcing plans to phase out routine animal toxicity testing for new drug candidates, aiming to make animal studies "the exception rather than the norm" within the next 3–5 years [89]. These developments challenge regulators and innovators to develop robust validation pathways for emerging platforms, but they also underscore a growing regulatory openness to modern predictive models.

2.5.2 | Regulatory Acceptance of Alternative Models

Determining appropriate contexts and evidence standards for using advanced in vitro systems, computational models, and other alternatives to traditional animal testing in regulatory submissions [42]. While regulatory agencies increasingly recognize the limitations of conventional models and the potential value of innovative alternatives, the process of establishing formal acceptance for specific applications remains complex, involving extensive validation, standardization, and demonstration of translational relevance. The transition toward "fit-for-purpose" validation approaches that match the rigor of validation to the context of use and regulatory impact offers a promising path forward but requires clear guidance and case examples [39]. Early successes in demonstrating alternative models' utility can catalyze acceptance. For instance, organ-on-chip systems have begun to show predictive power for human toxicity that exceeds animal models, as evidenced by a liver-chip correctly flagging hepatotoxic compounds missed in animal studies [90, 91]. Incorporation of such data as supportive evidence in Investigational New Drug (IND) submissions, under pilot qualification programs, could pave the way for broader regulatory confidence in these platforms [92]. International regulatory harmonization efforts, including initiatives by the FDA, EMA, and Japan's PMDA to share best practices on micro physiological systems, will be critical for aligning expectations and avoiding redundant requirements across jurisdictions [93].

2.5.3 | Data Standards and Submission Formats

Developing appropriate standards and formats for submitting, reviewing, and archiving complex data generated by advanced technologies, including multi-omics datasets, high-content imaging data, and computational model outputs [87]. The volume, heterogeneity, and technical complexity of these data create challenges for both sponsors preparing submissions and regulatory reviewers evaluating them, necessitating new approaches to data organization, visualization, and analysis. Collaborative initiatives between industry, technology providers, standards organizations, and regulatory agencies are essential for developing practical, widely adopted solutions that enhance both efficiency and transparency [34].

For example, standardized formats for whole-genome sequencing or transcriptomic data (such as the FASTQ and BAM formats) and agreed ontologies for cell types and phenotypic endpoints are being developed through consortia like the US FDA's SEND (Standard for Exchange of Nonclinical Data) for omics data [94]. The goal is to allow seamless incorporation of complex datasets into regulatory submissions and facilitate cross-study comparisons. Advanced visualization tools and reviewer training are also needed so that regulators can interrogate high-dimensional data (e.g., interactive genomic variant maps or single-cell clustering analyses) and glean meaningful conclusions for safety and efficacy assessments [32].

2.5.4 | Novel Therapeutic Modalities

Addressing the unique regulatory considerations associated with emerging therapeutic approaches, including cell and gene therapies, RNA-based treatments, multi-specific biologics, and targeted nanoparticles, which may not fit neatly within established regulatory frameworks and review pathways [29]. These innovative modalities often present distinctive challenges in manufacturing consistency, characterization, stability, safety assessment, and long-term monitoring that require adapted regulatory approaches and specialized expertise. The development of product-specific guidance's, specialized review pathways (such as the FDA's Office of Tissues and Advanced Therapies for cell/gene therapies), and adaptive regulatory frameworks helps address these challenges while providing greater predictability for developers [89]. Regulatory guidelines for RNA therapeutics now outline expectations for novel impurity profiles and immunogenicity testing distinct from traditional small molecules. For nanoparticle drug delivery systems, agencies have issued recommendations on characterization of particle size distributions and surface properties due to their critical impact on biodistribution. Continued dialogue between innovators and regulators through mechanisms like the FDA's Emerging Technology Program or Europe's Innovation Task Force is vital to anticipate and resolve modality-specific issues early in development [95].

2.5.5 | Real-World Evidence and Digital Endpoints

Establishing standards and methodologies for incorporating real-world data, digital biomarkers, and patient-generated health data into regulatory decision-making, complementing traditional clinical trial evidence [86]. While these approaches offer potential benefits in efficiency, representativeness, and patient-centricity, they also raise concerns about data quality, selection bias, confounding factors, and appropriate analytical methods that must be addressed through methodological standards and fit-for-purpose validation. The increasing integration of digital technologies in both drug discovery and clinical evaluation necessitates clear regulatory frameworks for evaluating and implementing these novel data sources and endpoints [9]. Regulators have begun pilot programs to use real-world evidence (RWE) for label expansions, and guidance documents (e.g., FDA's 2021 RWE draft guidance) outline how electronic health records and registry data might support effectiveness conclusions [96]. Similarly, digital health technologies such as wearable devices measuring

continuous activity or physiologic parameters are being qualified as digital endpoints (e.g., mobility measures in neurological diseases) after studies demonstrating their reliability and clinical relevance [42]. For advanced drug discovery, linking real-world patient data (such as genomic profiles linked to outcomes) back into target identification and validation represents an opportunity, but one that will require robust data curation and privacy safeguards acceptable to regulators and ethics boards.

2.5.6 | Global Regulatory Harmonization

Navigating differences in regulatory requirements, review processes, and acceptance of innovative approaches across international jurisdictions, which can create inefficiencies, delays, and strategic complexities for therapeutic development programs [32]. Despite progress through initiatives such as the International Council for Harmonization (ICH) and various bilateral agreements, significant regional variations persist in the evaluation and acceptance of advanced technologies, alternative testing methods, and novel therapeutic modalities [97]. These differences create particular challenges for global development programs and may influence strategic decisions about technology implementation, development pathways, and market prioritization. While U.S. regulations have started to accommodate organ-on-chip data in lieu of animal studies, some other regions may still require conventional toxicity tests, compelling sponsors to conduct both [33]. Similarly, the evidentiary threshold for approving gene therapies or adaptive trial designs may differ between the FDA, EMA, and other agencies. Continued harmonization efforts, such as ICH guidelines on adaptive clinical trials (ICH E20 in development) or multi-regional acceptance of non-animal toxicology models, are critical to ensure that advanced approaches can be adopted globally without duplicated effort [98]. Companies are increasingly engaging multiple agencies early via parallel scientific advice to identify divergent requirements and advocate for convergence in areas like next-generation sequencing data use or AI-driven analysis tools.

2.5.7 | Regulatory Science Capacity

Ensuring that regulatory agencies maintain sufficient scientific expertise, computational infrastructure, and methodological capabilities to effectively evaluate submissions incorporating advanced technologies and complex data [27]. The rapid pace of technological innovation creates challenges for regulatory agencies in recruiting and retaining staff with relevant expertise, developing appropriate review methodologies, and establishing internal policies and procedures for novel submission types [16]. These capacity constraints may contribute to review delays, inconsistent decision-making, or conservative approaches to innovative methods that could otherwise accelerate therapeutic development. To address this, agencies have invested in regulatory science programs and fellowships to build internal expertise in areas like bioinformatics, AI, and complex in vitro models. For example, the FDA's CDER has created an AI Steering Committee and is training reviewers on assessing ML algorithms and model bias [99]. Health Canada and EMA have similarly formed expert working groups on AI and digital health. Upgrading IT infrastructure is also a priority so that regulators can handle and securely store large datasets (e.g., raw sequencing data or high-resolution images) and run independent analyses if needed. In the long term, collaborative regulatory research such as FDA's participation in Micro physiological Systems development and in public-private partnerships like the Innovative Medicines Initiative in Europe will enhance agency familiarity with new technologies and facilitate the development of evaluation standards [88].

Addressing these regulatory challenges requires proactive, collaborative engagement from multiple stakeholders throughout the drug development ecosystem. Early consultation with regulatory agencies through formal and informal mechanisms, including scientific advice meetings, qualification programs, and innovation-focused initiatives such as the FDA's Complex Innovative Trial Designs Pilot Program, can help clarify expectations and identify potential concerns before significant resources are committed [89]. Similarly, participation in multi-stakeholder consortia and public-private partnerships focused on method validation, standards development, and regulatory science advancement can help shape evolving frameworks while distributing the burden of foundational work [37]. The COVID-19 pandemic has catalyzed regulatory innovation and adaptation, demonstrating the potential for more flexible, responsive oversight approaches without compromising fundamental standards for safety and efficacy [30]. Accelerated review processes, innovative clinical trial designs, enhanced international collaboration, and pragmatic approaches to manufacturing scale-up all contributed to the unprecedented speed of therapeutic and vaccine development during the pandemic. These experiences provide valuable lessons and precedents for regulatory approaches to advanced technologies and integrated development strategies more broadly, potentially informing lasting reforms that better balance innovation with appropriate oversight [24]. As biotechnology platforms continue to evolve and converge, ongoing dialogue and collaboration between technology developers, drug discovery scientists, regulatory experts, and policy makers will be essential for developing appropriate regulatory frameworks that protect public health while facilitating therapeutic innovation [22]. This dialogue should address not only technical and scientific considerations but also broader societal and ethical implications of advanced technologies, ensuring that regulatory approaches reflect diverse perspectives and values while remaining grounded in sound scientific principles.

2.6 | Future Directions

The coming years are poised to see even deeper integration of technology platforms and novel methodologies that will push the boundaries of drug discovery [1, 3, 4]. One prominent trend is the advancement of precision medicine facilitated by integrated data approaches. As multi-omics profiling of patients becomes more routine and as large-scale biobanks link genomic data with clinical outcomes, AI-driven analyses will identify ever more refined patient subgroups for various diseases [22, 39]. Drug discovery can leverage these insights by developing therapies tailored to molecularly defined subpopulations, moving away from one-size-fits-all treatments. The convergence of AI, multi omics profiling and

large-scale clinical data is expected to make drug development increasingly tailored to specific patient groups. AI models trained on integrated omics datasets (genomic variants, transcriptomic signatures, proteomic patterns and metabolomic states) alongside real world clinical variables such as age, comorbidities, tumor subtype and treatment history can identify distinct molecular subpopulations with unique therapeutic vulnerabilities [75]. Such stratification has already been demonstrated in oncology, where machine learning applied to The Cancer Genome Atlas (TCGA) datasets has classified patients into actionable molecular subgroups and predicted differential responses to targeted therapy [100]. As biobanks grow and more patients undergo routine sequencing, AI systems will be able to link longitudinal clinical outcomes with multi omics patterns, enabling precise prediction of which therapeutic modalities small molecules, biologics or combination regimens will be most effective for each subgroup [101]. In parallel, patient derived organoids and ex vivo models from these subgroups can experimentally validate AI prioritized targets or drug candidates, closing the loop between computation and functional biology [102]. Such integrated frameworks will shift drug development from broad population-based approaches toward precision stratified programmes that design, test and optimize therapies for clearly defined patient cohorts, improving efficacy while reducing unnecessary exposure to ineffective treatments [103]. Future drug discovery programs will routinely originate from vast repositories of disease data such as mutational landscapes and gene expression signatures enabling AI to pinpoint promising targets and select optimal therapeutic modalities for specific patient segments [42]. Organoid and other patient-derived models from those subgroups could be used in parallel to validate target biology and screen candidate compounds, thus embedding a translational mindset from the earliest stages of development.

On the technological front, next-generation organoids and micro physiological systems will likely address current model limitations [57]. For instance, incorporation of microvascular networks into organoids via bioengineering or self-organizing endothelial cells could allow these models to better predict drug distribution and immune interactions [34]. Multi-organ "body-on-a-chip" platforms, which connect different organoid or tissue-chip modules, are in development to simulate systemic pharmacokinetics and cross-organ toxicities in vitro [33]. The integration of such systems with real-time sensors and microfluidic control will produce continuous data streams that AI can analyze on-the-fly, enabling adaptive experimentation where dosing or conditions are adjusted in real time based on model feedback [40]. This kind of closed-loop experimentation represents a convergence of lab automation, AI, and advanced models that could significantly speed up optimization cycles for drug candidates.

Meanwhile, AI and computational modelling are expected to become even more powerful and ubiquitous. Large-scale pre-trained models (sometimes called foundation models) in chemistry and biology could be fine-tuned for specific drug discovery tasks, making sophisticated predictions available to non-experts through user-friendly interfaces [24]. Improved interpretability and causal reasoning in AI models are actively being pursued, which should help in gaining regulatory trust and clinical acceptance for AI-assisted decisions. Additionally, nascent technologies like quantum computing hold promise for tackling complex molecular simulations and optimization problems that are currently beyond the reach of classical computation [16]. If realized, quantum-accelerated drug discovery algorithms might explore chemical space or protein-ligand interactions with unprecedented speed and accuracy, further empowering AI-driven design.

Another area poised for growth is the use of in silico clinical trials and virtual patient cohorts. As integrated models and simulations improve, researchers may simulate certain aspects of trials (such as drug efficacy in virtual populations with varying genetics) to predict outcomes and refine trial designs before actual human studies [30]. While these simulations will not replace real clinical trials, they could optimize key parameters (e.g., dosing, inclusion criteria, combination strategies) to increase the probability of success. Regulatory bodies have shown interest in model-informed drug development, and future guidance might incorporate the use of validated predictive models as supportive evidence alongside experimental data [47, 67].

Realizing these future advances will require continued collaboration and data sharing. The complexity of integrated drug discovery means no single organization can excel in all aspects; we anticipate more consortium-based efforts where industry, academia, and government labs pool expertise and data [66]. Secure platforms for sharing data and AI models (such as federated learning frameworks that protect sensitive patient data while allowing algorithm training) can facilitate this collective progress. Furthermore, training and education will be key, future scientists will benefit from interdisciplinary curricula that cover computational sciences, bioengineering, and pharmacology, ensuring they are well-equipped to work in integrated research environments [39].

In summary, the future of drug discovery will likely be characterized by even tighter synergy between experimental and computational methods, greater personalization of therapies, and a more networked approach to R&D [8, 58]. If the current momentum continues, integrated biotechnology platforms will not only enhance the efficiency of discovering new drugs but also transform the kinds of therapies we develop enabling treatments that are more precisely tailored to the biology of each disease and each patient.

3 | Conclusion

The integration of advanced biotechnology platforms has fundamentally transformed the landscape of drug discovery, creating unprecedented opportunities for therapeutic innovation while simultaneously presenting new challenges for researchers, organizations, and regulatory systems. In this review, we have examined the diverse technological platforms that comprise the modern drug discovery toolkit from computational methods and high-throughput screening systems to advanced cellular models and multi-omics approaches, highlighting both their individual capabilities and their synergistic potential when thoughtfully combined. The emergence of these powerful technologies, alongside a deepening understanding of disease biology and growing healthcare needs, has catalyzed a reimagining of drug discovery

processes and strategies with far-reaching implications for the future of medicine.

Several key themes emerge from our analysis of integrated biotechnology platforms in drug discovery. First, the convergence of diverse technological approaches creates capabilities greater than the sum of their individual contributions. The combination of AI-driven target prediction with CRISPR-based validation, advanced screening platforms with sophisticated cellular models, and multi-omics profiling with integrative computational analysis enables a more comprehensive exploration of biological complexity and therapeutic opportunity than any single approach alone. Organizations that effectively integrate these complementary capabilities can potentially achieve transformative improvements in R&D productivity, therapeutic innovation, and clinical impact. Second, the effective implementation of advanced technologies requires not merely technical expertise but also thoughtful integration strategies that address organizational, cultural, and epistemological dimensions of innovation. Investments in modular infrastructures, transdisciplinary teams, continuous learning systems, and collaborative ecosystems provide frameworks for navigating the increasing complexity of drug discovery methodologies. Third, the rapid evolution of biotechnology platforms creates both opportunities and challenges for regulatory systems, necessitating adaptive oversight that maintains rigorous standards while accommodating novel methodologies. Early engagement with regulators, participation in method-qualification initiatives, and contributions to standards development can help align technological innovation with regulatory expectations, reducing uncertainty and facilitating efficient development pathways. Fourth, the growing power and complexity of these tools heighten the importance of strong foundational knowledge in disease biology and translational strategy. Advanced technologies can amplify our exploratory reach but cannot compensate for weak biological hypotheses or poorly defined clinical needs. Thus, technological capabilities must be paired with robust expertise in pathology and clinical research to translate potential leads into meaningful therapeutic advances. Finally, the shift toward more integrated, data-rich approaches creates new possibilities for precision medicine, moving drug development from a search for broadly applicable treatments toward the creation of targeted therapies tailored to specific patient subgroups based on molecular and phenotypic characteristics. This promises to improve treatment outcomes and reduce unnecessary exposure to ineffective therapies, fulfilling a long-standing goal of pharmaceutical research.

In conclusion, integrating AI, organoids, multi-omics, and related technologies represents both a tremendous opportunity and a complex challenge for drug discovery in the 21st century. When combined effectively, these platforms can address many limitations of traditional approaches and significantly enhance the pipeline from drug conception to clinical success. Realizing this potential will require continued innovation, rigorous validation, and a cooperative effort among scientists, clinicians, industry leaders, and regulators. The encouraging progress to date suggests that a more efficient, precise, and patient-centric era of drug discovery is on the horizon an era in which translational medicine is accelerated by the seamless blending of advanced biotechnology platforms.

Author Contributions

Yuvaraj and Saravanakumar:- Conceptualization, Original draft and validation; Rinish and Aishwarya:- Draft preparation, Figures and software; Harshaveena:- Language editing; Arokiyaraj: – Resources; Punitha and Venkatesh: —Validation.

Funding

No funding was received for this work

Conflicts of Interest

The authors declare no conflicts of interest.

References

1. T. P. Theodore Armand, K. A. Nfor, J. I. Kim, and H. C. Kim, "Applications of Artificial Intelligence, Machine Learning, and Deep Learning in Nutrition: A Systematic Review," *Nutrients* 16 (2024): 1073.

2. S. Padte, V. S. Venkata, P. Mehta, S. Tawfeeq, R. Kashyap, and S. Surani, "21st Century Critical Care Medicine: An Overview," *World Journal of Critical Care Medicine* 13 (2024): 90176.

3. C. Fu and Q. Chen, "The Future of Pharmaceuticals: Artificial Intelligence in Drug Discovery and Development," *Journal of Pharmaceutical Analysis* 15 (2025): 101248.

4. D. R. Serrano, F. C. Luciano, B. J. Anaya, et al., "Artificial Intelligence (AI) Applications in Drug Discovery and Drug Delivery: Revolutionizing Personalized Medicine," *Pharmaceutics* 16 (2024): 1328.

5. N. A. Colwell, "Harnessing Artificial Intelligence in Drug Discovery and Development 2024," accessed July 9, 2025, https://www.accc-cancer.org/acccbuzz/blog-post-template/accc-buzz/2024/12/20/harnessing-artificial-intelligence-in-drug-discovery-and-development.

6. D. Domingo-Fernández, Y. Gadiya, A. J. Preto, et al., "Natural Products Have Increased Rates of Clinical Trial Success Throughout the Drug Development Process," *Journal of Natural Products* 87 (2024): 1844–1851.

7. I. Gopallawa, C. Gupta, R. Jawa, et al., "Applications of Organoids in Advancing Drug Discovery and Development," *Journal of Pharmaceutical Sciences* 113 (2024): 2659–2667.

8. A. Santos-Filho, R. Dhudum, A. Ganeshpurkar, and A. Pawar, "Revolutionizing Drug Discovery: A Comprehensive Review of AI Applications," *Drugs and Drug Candidates* 3 (2024): 148–171.

9. M. J. Lamberti, M. Wilkinson, B. A. Donzanti, et al., "A Study on the Application and Use of Artificial Intelligence to Support Drug Development," *Clinical Therapeutics* 41 (2019): 1414–1426.

10. C. P. Austin, "Opportunities and Challenges in Translational Science," *Clinical and Translational Science* 14 (2021): 1629.

11. M. Popova, O. Isayev, and A. Tropsha, "Deep Reinforcement Learning for De Novo Drug Design," *Science Advances* 4 (2018):aap7885.

12. L. Wang, J. Ding, L. Pan, D. Cao, H. Jiang, and X. Ding, "Artificial Intelligence Facilitates Drug Design in the Big Data Era," *Chemometrics and Intelligent Laboratory Systems* 194 (2019): 103850.

13. K. H. Nam, "Evaluation of AlphaFold3 for the Fatty Acids Docking to Human Fatty Acid-Binding Proteins," *Journal of Molecular Graphics and Modelling* 133 (2024): 108872.

14. K. K. Mak and M. R. Pichika, "Artificial Intelligence in Drug Development: Present Status and Future Prospects," *Drug Discovery Today* 24 (2019): 773–780.

15. J. A. M. Sidey-Gibbons and C. J. Sidey-Gibbons, "Machine Learning in Medicine: A Practical Introduction," *BMC Medical Research Methodology* 19 (2019): 64.

16. J. C. F. Silva, R. M. Teixeira, F. F. Silva, S. H. Brommonschenkel, and E. P. B. Fontes, "Machine Learning Approaches and Their Current

Application in Plant Molecular Biology: A Systematic Review," *Plant Science* 284 (2019): 37–47.

17. A. Zhavoronkov, Y. A. Ivanenkov, A. Aliper, et al., "Deep Learning Enables Rapid Identification of Potent DDR1 Kinase Inhibitors," *Nature Biotechnology* 37 (2019): 1038–1040.

18. L. Peng, R. Hu, F. Kong, et al., "Reverse Graph Learning for Graph Neural Network," *IEEE Transactions on Neural Networks and Learning Systems* 35 (2022): 4530–4541.

19. J. Li, Q. Sun, and F. Zhang, "Meta-Structure-Based Graph Attention Networks," *Neural Networks* 171 (2024): 362–373.

20. G. A. Lyngdoh, H. Li, M. Zaki, N. M. Anoop Krishnan, and S. Das, "Elucidating the Constitutive Relationship of Calcium–Silicate–Hydrate Gel Using High Throughput Reactive Molecular Simulations and Machine Learning," *Scientific Reports* 10 (2020): 21336.

21. A. Lavecchia and C. Cerchia, "In Silico Methods to Address Polypharmacology: Current Status, Applications and Future Perspectives," *Drug Discovery Today* 21 (2016): 288–298.

22. Y. Shi, L. Bao, Y. Li, et al., "Multi-Omics Combined to Investigate Potential Druggable Therapeutic Targets for Stroke: A Systematic Mendelian Randomization Study and Transcriptome Verification," *Journal of Affective Disorders* 366 (2024): 196–209.

23. O. M. Ajisafe, Y. A. Adekunle, E. Egbon, C. E. Ogbonna, and D. B. Olawade, "The Role of Machine Learning in Predictive Toxicology: A Review of Current Trends and Future Perspectives," *Life Sciences* 378 (2025): 123821.

24. R. J. Bienstock, "AI/ML Methodologies and the Future-Will They be Successful in Designing the next Generation of New Chemical Entities?," *Journal of Cheminformatics* 17 (2025): 1–6.

25. F. Ren, A. Aliper, J. Chen, et al., "A Small-Molecule TNIK Inhibitor Targets Fibrosis in Preclinical and Clinical Models," *Nature Biotechnology* 43 (2025): 63–75.

26. Z. Xu, F. Ren, P. Wang, et al., "A Generative AI-Discovered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis: A Randomized Phase 2a Trial," *Nature Medicine* 31 (2025): 2602–2610.

27. S. Masarone, K. V. Beckwith, M. R. Wilkinson, et al., "Advancing Predictive Toxicology: Overcoming Hurdles and Shaping the Future," *Digital Discovery* 4 (2025): 303–315.

28. S. Garg, C.-H. Lardeau, and E. Mouchet, "Assay Development and Automation in High Content Screening. High Content Imaging in Drug Discovery," in *High Content Imaging in Drug Discovery* (ResearchGate, 2025), 26–74.

29. F. Stossi, P. K. Singh, K. Safari, M. Marini, D. Labate, and M. A. Mancini, "High Throughput Microscopy and Single Cell Phenotypic Image-Based Analysis in Toxicology and Drug Discovery," *Biochemical Pharmacology* 216 (2023): 115770.

30. L. Funk, K.-C. Su, J. Ly, et al., "The Phenotypic Landscape of Essential human Genes," *Cell* 185 (2022): 4634–4653.

31. M. J. Cox, S. Jaensch, J. Van de Waeter, et al., "Tales of 1,008 Small Molecules: Phenomic Profiling Through Live-Cell Imaging in a Panel of Reporter Cell Lines," *Scientific Reports* 10 (2020): 13262.

32. R. Gayathri, S. Kar, M. Nagai, F.-G. Tseng, P. S. Mahapatra, and T. S. Santra, "Single-Cell Patterning: A New Frontier in Bioengineering," *Materials Today Chemistry* 26 (2022): 101021.

33. M. S. Yousafzai and J. A. Hammer, "Using Biosensors to Study Organoids, Spheroids and Organs-on-a-Chip: A Mechanobiology Perspective," *Biosensors* 13 (2023): 905.

34. L. Bai, Y. Wu, G. Li, W. Zhang, H. Zhang, and J. Su, "AI-Enabled Organoids: Construction, Analysis, and Application," *Bioactive Materials* 31 (2024): 525–548.

35. H. Wang, J. Huang, X. Fang, M. Liu, X. Fan, and Y. Li, "Advances in next-generation Sequencing (NGS) Applications in Drug Discovery and Development," *Expert Opinion on Drug Discovery* 20 (2025): 537–550.

36. I. Berger Fridman, J. Kostas, M. Gregus, et al., "High-throughput Microfluidic 3D Biomimetic Model Enabling Quantitative Description of the Human Breast Tumor Microenvironment," *Acta Biomaterialia* 132 (2021): 473–488.

37. F. Meissner, J. Geddes-McAlister, M. Mann, and M. Bantscheff, "The Emerging Role of Mass Spectrometry-based Proteomics in Drug Discovery," *Nature Reviews Drug Discovery* 21 (2022): 637–654.

38. A. Leitner, "A Review of the Role of Chemical Modification Methods in Contemporary Mass Spectrometry-Based Proteomics Research," *Analytica Chimica Acta* 1000 (2018): 2–19.

39. C. Shi, L. Cheng, Y. Yu, et al., "Multi-Omics Integration Analysis: Tools and Applications in Environmental Toxicology," *Environmental Pollution* 360 (2024): 124675.

40. D. Watanabe, M. Hiroshima, M. Yasui, and M. Ueda, "Single Molecule Tracking Based Drug Screening," *Nature Communications* 15 (2024): 8975.

41. H. Jin, L. Wang, and R. Bernards, "Rational Combinations of Targeted Cancer Therapies: Background, Advances and Challenges," *Nature Reviews Drug Discovery* 22 (2022): 213–234.

42. N. Biswas and S. Chakrabarti, "Artificial Intelligence (AI)-Based Systems Biology Approaches in Multi-Omics Data Analysis of Cancer," *Frontiers in Oncology* 10 (2020): 588221.

43. G. Rossi, A. Manfrin, and M. P. Lutolf, "Progress and Potential in Organoid Research," *Nature Reviews Genetics* 19 (2018): 671–687.

44. S. Chen, X. Chen, Z. Geng, and J. Su, "The Horizon of Bone Organoid: A Perspective on Construction and Application," *Bioactive Materials* 18 (2022): 15–25.

45. E. de Poel, J. W. Lefferts, and J. M. Beekman, "Intestinal Organoids for Cystic Fibrosis Research," *Journal of Cystic Fibrosis* 19 (2020): S60–S64.

46. S. K. Ray and S. Mukherjee, "Imitating Hypoxia and Tumor Microenvironment With Immune Evasion by Employing Three Dimensional In Vitro Cellular Models: Impressive Tool in Drug Discovery," *Recent Patents on Anti-Cancer Drug Discovery* 17 (2021): 80–91.

47. G. Kaushik, M. P. Ponnusamy, and S. K. Batra, "Concise Review: Current Status of Three-Dimensional Organoids as Preclinical Models," *Stem Cells* 36 (2018): 1329–1340.

48. H. Liu, Y. Wang, K. Cui, Y. Guo, X. Zhang, and J. Qin, "Advances in Hydrogels in Organoids and Organs-on-a-Chip," *Advanced Materials* 31 (2019): 1902042.

49. Q.-J. Mei, J.-Q. Wen, X.-X. Xu, and H.-Q. Xie, "Generation of Vascularized Brain Organoids: Technology, Applications, and Prospects," *Organoid Research* 1, no. 2 (2025): 8162.

50. Y. Jin, Q. Chen, L. Gong, et al., "Organoids: Applications and Challenges of Advanced Hydrogels in Tissue Systems," *Organoid Research* 1, no. 2 (2025): 8262.

51. L. Bai, Y. Jing, R. L. Reis, X. Chen, J. Su, and C. Liu, "Organoid Research: Theory, Technology, and Therapeutics," *Organoid Research* 1, no. 1 (2025): 025040007.

52. D. Blondel and M. P. Lutolf, "Bioinspired Hydrogels for 3D Organoid Culture," *Chimia* 73 (2019): 81.

53. M. Sakalem, S. M. De, F. Costa, and M. Oliveira, "Historical Evolution of Spheroids and Organoids, and Possibilities of Use in Life Sciences and Medicine," *Biotechnology Journal* 16 (2021): 2000463.

54. J. P. Licata, K. H. Schwab, H.-Y. El, J. A. Gerstenhaber, and P. I. Lelkes, "Bioreactor Technologies for Enhanced Organoid Culture," *International Journal of Molecular Sciences* 24 (2023): 11427.

55. K. Li, Y. He, X. Jin, K. Jin, and J. Qian, "Reproducible Extracellular Matrices for Tumor Organoid Culture: Challenges and Opportunities," *Journal of Translational Medicine* 23 (2025): 497.

56. R. Millen, W. W. B. De Kort, M. Koomen, et al., "Patient-derived Head and Neck Cancer Organoids Allow Treatment Stratification and Serve as a Tool for Biomarker Validation and Identification," *Medicine* 4 (2023): 290–310.

57. S. Maramraju, A. Kowalczewski, A. Kaza, et al., "AI-Organoid Integrated Systems for Biomedical Studies and Applications," *Bioengineering & Translational Medicine* 9 (2024): 10641.

58. P. Du, R. Fan, N. Zhang, C. Wu, and Y. Zhang, "Advances in Integrated Multi-Omics Analysis for Drug-Target Identification," *Biomolecules* 14 (2024): 692.

59. N. G. Reitsam, J. S. Enke, K. Vu Trung, B. Märkl, and J. N. Kather, "Artificial Intelligence in Colorectal Cancer: From Patient Screening Over Tailoring Treatment Decisions to Identification of Novel Biomarkers," *Digestion* 105 (2024): 331–344.

60. S. P. In, "Silico Strategies for Cancer Model Development and Anticancer Drug Testing," in *Preclinical Cancer Models for Translational Research and Drug Development* (Springer, 2025), 153–168.

61. J. He, X. Hu, L. Chen, and Y. Jiang, "Application of Multi-omics in Hepatocellular Carcinoma: New Prospects for Classification and Precise Diagnosis and Treatment," *Hepatoma Research* 11 (2025): 6.

62. S. Seal, M. Mahale, M. García-Ortegón, et al., "Machine Learning for Toxicity Prediction Using Chemical Structures: Pillars for Success in the Real World," *Chemical Research in Toxicology* 38 (2025): 759–807.

63. S. Vinga, "Structured Sparsity Regularization for Analyzing High-Dimensional Omics Data," *Briefings in Bioinformatics* 22 (2021): 77–87.

64. B. Chen, L. Garmire, D. F. Calvisi, M. S. Chua, R. K. Kelley, and X. Chen, "Harnessing Big 'Omics' Data and AI for Drug Discovery in Hepatocellular Carcinoma," *Nature Reviews Gastroenterology & Hepatology* 17 (2020): 238–251.

65. M. Brendel, C. Su, Z. Bai, H. Zhang, O. Elemento, and F. Wang, "Application of Deep Learning on Single-Cell RNA Sequencing Data Analysis: A Review," *Genomics, Proteomics & Bioinformatics* 20 (2022): 814–835.

66. O. Kapustina, P. Burmakina, N. Gubina, N. Serov, and V. Vinogradov, "User-Friendly and Industry-Integrated AI for Medicinal Chemists and Pharmaceuticals," *Artificial Intelligence Chemistry* 2 (2024): 100072.

67. R. Bhattacharya, D. Bose, T. Kaur, R. Patel, O. Renuka, and R. V. Rodriguez, "Model Organoids: Integrated Frameworks for the Next Frontier of Healthcare Advancements," *Stem Cell Reviews and Reports* 21 (2025): 319–336.

68. D. M. Aasen and M. N. Vergara, "New Drug Discovery Paradigms for Retinal Diseases: A Focus on Retinal Organoids," *Journal of Ocular Pharmacology and Therapeutics* 36 (2020): 18–24.

69. G. W. W. Bin, W. Wang, and L. Wong, "Why Batch Effects Matter in Omics Data, and How to Avoid Them," *Trends in Biotechnology* 35 (2017): 498–507.

70. E. Elfatimi, Y. Lekbach, S. Prakash, et al., "Artificial Intelligence-, Organoid-, and Organ-on-Chip-Powered Models to Improve Pre-Clinical Animal Testing of Vaccines and Immunotherapeutics: Potential, Progress, and Challenges," *Frontiers in Artificial Intelligence* 8 (2025): 1681106.

71. M. R. Uddin, M. S. I. Sovon, S. Mondal, et al., "Artificial Intelligence and Machine Learning in Pharmaceutical Sciences: Unpacking Regulatory Guidance, Opportunities, and Challenges for Safe and Effective Drug Development," *SSRN* (2025): 50.

72. F. Mirakhori and S. K. Niazi, "Harnessing the AI/ML in Drug and Biological Products Discovery and Development: The Regulatory Perspective," *Pharmaceuticals* 18 (2025): 47.

73. S. Gundlapalli and T. Bill, "The Application of Organ-on-a-Chip Technology for Disease Modeling and Drug Testing," *Acta Scientific Medical Sciences* 9, no. 7 (2025): 24–37.

74. P. C. Tiwari, R. Pal, M. J. Chaudhary, and R. Nath, "Artificial Intelligence Revolutionizing Drug Development: Exploring Opportunities and Challenges," *Drug Development Research* 84 (2023): 1652–1663.

75. A. Yetgin, "Revolutionizing Multi-Omics Analysis With Artificial Intelligence and Data Processing," *Quantitative Biology* 13 (2025): 70002.

76. A. Mukherjee, S. Abraham, A. Singh, S. Balaji, and K. S. Mukunthan, "From Data to Cure: A Comprehensive Exploration of Multi-omics Data Analysis for Targeted Therapies," *Molecular Biotechnology* 67 (2024): 1269–1289.

77. B. S. Park, M. Lee, J. Kim, and T. Kim, "Perturbomics: CRISPR–Cas Screening-Based Functional Genomics Approach for Drug Target Discovery," *Experimental & Molecular Medicine* 57 (2025): 1443–1454.

78. Y. Li, L. Ma, D. Wu, and G. Chen, "Advances in Bulk and Single-Cell Multi-Omics Approaches for Systems Biology and Precision Medicine," *Briefings in Bioinformatics* 22 (2021): 1–18.

79. N. Brandenberg, S. Hoehnel, F. Kuttler, et al., "High-Throughput Automated Organoid Culture via Stem-cell Aggregation in Microcavity Arrays," *Nature Biomedical Engineering* 4 (2020): 863–874.

80. J. Lewis and S. Holm, "Organoid Biobanking, Autonomy and the Limits of Consent," *Bioethics* 36 (2022): 742–756.

81. M. Salmi, D. Atif, D. Oliva, A. Abraham, and S. Ventura, "Handling Imbalanced Medical Datasets: Review of a Decade of Research," *Artificial Intelligence Review* 57 (2024): 273.

82. A. M. Conard, A. DenAdel, and L. Crawford, "A Spectrum of Explainable and Interpretable Machine Learning Approaches for Genomic Studies," *WIREs Computational Statistics* 15 (2023): 1617.

83. B. Dou, Z. Zhu, E. Merkurjev, et al., "Machine Learning Methods for Small Data Challenges in Molecular Science," *Chemical Reviews* 123 (2023): 8736–8780.

84. A. Gangwal, A. Ansari, I. Ahmad, et al., "Generative Artificial Intelligence in Drug Discovery: Basic Framework, Recent Advances, Challenges, and Opportunities," *Frontiers in Pharmacology* 15 (2024): 1331062.

85. L. Frusciante, A. Visibelli, M. Geminiani, A. Santucci, and O. Spiga, "Artificial Intelligence Approaches in Drug Discovery: Towards the Laboratory of the Future," *Current Topics in Medicinal Chemistry* 22 (2022): 2176–2189.

86. A. Bond, K. Mccay, and S. Lal, "Artificial Intelligence & Clinical Nutrition: What the Future Might Have in Store," *Clinical Nutrition* 57 (2023): 542–549.

87. M. van Erp, C. Reynolds, D. Maynard, et al., "Using Natural Language Processing and Artificial Intelligence to Explore the Nutrition and Sustainability of Recipes and Food," *Frontiers in Artificial Intelligence* 3 (2021): 621577.

88. J. Williams, "FDA Modernization Act 2.0: The Beginning of the End for Animal Testing in Drug Development," *Animal Law* 30 (2024): 139.

89. A. Mullard, "Is the FDA's Plan to Phase out Animal Toxicity Testing Realistic?," *Nature Reviews Drug Discovery* 24 (2025): 413–414.

90. M. R. Schneider, M. Oelgeschlaeger, T. Burgdorf, et al., "Applicability of Organ-on-chip Systems in Toxicology and Pharmacology," *Critical Reviews in Toxicology* 51 (2021): 540–554.

91. T. Messelmani, L. Morisseau, Y. Sakai, et al., "Liver Organ-on-chip Models for Toxicity Studies and Risk Assessment," *Lab on a Chip* 22 (2022): 2423–2450.

92. P. Nugent, J. N. Duncan, and D. B. Colagiovanni, "Preparation of a Preclinical Dossier to Support an Investigational New Drug (IND) Application and First-In-Human Clinical Trial. A Comprehensive Guide to Toxicology in Nonclinical Drug Development," in *A Comprehensive Guide to Toxicology in Nonclinical Drug Development (Second Edition)* (Academic Press, 2017), 189–213.

93. C. Amaral, M. Paiva, A. R. Rodrigues, F. Veiga, and V. Bell, "Global Regulatory Challenges for," *Medical Devices: Impact on Innovation and Market Access Applied Sciences* 14 (2024): 9304.

94. S. K. Niazi, "A Critical Analysis of the FDA's Omics-Driven Pharmacodynamic Biomarkers to Establish Biosimilarity," *Pharmaceuticals* 16 (2023): 1556.

95. K. Mehta, C. Maass, L. Cucurull-Sanchez, et al., "Modernizing Preclinical Drug Development: The Role of New Approach Methodologies," *ACS Pharmacology & Translational Science* 8 (2025): 1513–1525.

96. C. M. Conceição, P. Monografia Orientada Pela, P. Doutora, C. Torre, P. Auxiliar, and D. Fful, *Mapping the Landscape of Real-World Evidence (RWE) Guidance and Initiatives Across Regulatory Jurisdictions* (Repositório Da Universidade de Lisboa, 2024).

97. S. K. Niazi, W. M. Al-Shaqha, and Z. Mirza, "Proposal of International Council for Harmonization (ICH) Guideline for the Approval of Biosimilars," *Journal of Market Access & Health Policy* 11 (2023): 2147286.

98. R. Singh, W. Wang, A. Chakravarty, J. Wang, and Y. Uyama, "Simultaneous Global Drug Development and Multiregional Clinical Trials (MRCT): 5 Years after Implementation of ICH E17 Guidelines," *Therapeutic Innovation & Regulatory Science* 58 (2024): 845–854.

99. J. K. Chaudhari, S. Pant, R. Jha, R. K. Pathak, and D. B. Singh, "Biological Big-data Sources, Problems of Storage, Computational Issues, and Applications: A Comprehensive Review," *Knowledge and Information Systems* 66 (2024): 3159–3209.

100. J. Liñares-Blanco, A. Pazos, and C. Fernandez-Lozano, "Machine Learning Analysis of TCGA Cancer Data," *PeerJ Computer Science* 7 (2021): 1–47.

101. M. Zack, D. N. Stupichev, A. J. Moore, et al., "Artificial Intelligence and Multi-Omics in Pharmacogenomics: A New Era of Precision Medicine," *Mayo Clinic Proceedings: Digital Health* 3 (2025): 100246.

102. X. Han, C. Cai, W. Deng, et al., "Landscape of human Organoids: Ideal Model in Clinics and Research," *Innovation* 5 (2024): 100620.

103. A. S. Walker, I. R. White, R. M. Turner, et al., "Personalised Randomised Controlled Trial Designs—A New Paradigm to Define Optimal Treatments for Carbapenem-Resistant Infections," *Lancet Infectious Diseases* 21 (2021): e175–e181.